Karyopharm Therapeutics, Inc. KPTI 深 滬
等待開盤 08-21 09:30:00 美东时间
1.82
-0.180
-9.00%
華盛通- 最 高2.00
- 今 開2.00
- 成交量 86.56万股
- 最 低 1.82
- 昨 收 2.00
- 總市值 4.13万
- 52周最高 10.99
- 市盈率 靜 --
- 換手率 3816.54%
- 52周最低 1.79
- 委 比 95.44%
- 總股本 2.27万
- 歷史最高 735.075
- 量 比 0.73
- 振 幅 9.00%
- 歷史最低 1.79
- 每 手 1
- 風險率 1.89%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Karyopharm Therapeutics Affirms FY2026 Sales Guidance of $130.000M-$150.000M vs $133.736M Est
Karyopharm Therapeutics (NASDAQ:KPTI) affirms FY2026 sales outlook from $130.000 million-$150.000 million to $130.000 million-$150.000 million vs $133.736 million estimate.
08-13 19:32
Zenas BioPharma Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Zenas BioPharma reported financial results for Q2 2026 and provided updates on its pipeline. The FDA accepted the BLA for obexelimab to treat IgG4-RD with a PDUFA date of May 27, 2027. New bioequivalence data for obexelimab's delivery methods were confirmed. Phase 2 SunStone SLE trial results are expected in Q4 2026. ZB021's Phase 1 trial is ongoing, with initial data anticipated by year-end. Four abstracts for orelabrutinib were accepted for MST...
08-13 11:00
德琪医药合作伙伴Karyopharm拟通过加速批准途径提交塞利尼索联合芦可替尼治...
德琪医药合作伙伴Karyopharm Therapeutics Inc.（纳斯达克代码：KPTI）近日宣布，计划于2026年8月向美国食品药品监督管理局（FD...
08-06 09:58
美股大行评级 | 最高400美元！亚马逊绩后获11家大行上调目标价；苹果绩后评级分歧大！3家上调，3家下调；德康医疗、万事达、神经分泌生物科学获多家大行上调目标价
今日重点评级关注：TD Cowen：维持加拿大鹅"买入"评级，目标价从13美元升至18美元；瑞银：维持吉登运动服"买入"评级，目标价从110美元升至111美元
08-03 11:38
GoDaddy, NXT, Karyopharm, AXT, Enbridge Trending With Analysts
Analysts are intrested in these 5 stocks: ( ($GDDY) ), ( ($NXT) ), ( ($KPTI) ),...
08-01 17:02
美股夜盘 | AXT Inc涨22.92%，Ryan Specialty Holdings, Inc. Class A涨11.14%
Karyopharm Therapeutics, Inc.涨-69.61%；NUWELLIS涨-36.85%；T3 Defense涨-19.48%
07-31 08:05
Karyopharm Therapeutics To Submit FDA Supplemental New Drug Application In August 2026 For Accelerated Approval Of Selinexor In Combination With Ruxolitinib To Treat Myelofibrosis
– Following FDA Engagements, Company Plans to Submit sNDA under Accelerated Approval Based Upon Compelling SVR35 Data and Preliminary Overall Survival Data Observed at the Time of the Topline Results – – Company Plans to Use Long-Term Overall Survival Data from the Ongoing Phase 3 SENTRY Trial to Ve...
07-31 04:11
Karyopharm drops 21% following disclosure of executive cash retention plan
Karyopharm Pharmaceuticals (KPTI) closed Monday down ~21% after disclosing a "2026 Leadership Cash Retention Program" for some of its top executives. Those who will benefit from it are its CEO, CFO, c...
07-21 04:57
Karyopharm Launches 2026 Executive Retention Incentive Program
Karyopharm Therapeutics ( ($KPTI) ) has issued an update. On July 13, 2026, Kar...
07-18 11:32
Dyne Therapeutics Appoints Barry Greene to Board of Directors
Dyne Therapeutics announced the appointment of Barry Greene to its Board of Directors. With over three decades of experience in the biopharmaceutical industry, Greene brings a proven track record of building and scaling innovative companies across rare diseases, neuroscience, and oncology. His leadership includes roles at Sage Therapeutics and Alnylam Pharmaceuticals, where he contributed to the development and commercialization of novel therapie...
06-22 20:10
